Status:
COMPLETED
Efficacy and Safety of Anthrax Vaccine, GC1109
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Green Cross Corporation
LSK Global Pharma Services Co. Ltd.
Conditions:
Anthrax
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
1. BACKGROUND The newly developed anthrax vaccine GC1109 has been proven safe and effective in preclinical studies. 2. OBJECTIVE \- To evaluate the immunogenicity and safety of the anthrax vaccine...
Eligibility Criteria
Inclusion
- Healthy male subjects between 18 and 45 years of age at the time of screening visit
- 18.5kg/m2 ≤BMI \< 30kg/m2 at the time of screening visit
- Subjects without congenital or chronic disorder
Exclusion
- \-
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01867957
Start Date
February 1 2009
End Date
December 1 2009
Last Update
June 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea